統合失調症に伴う認知障害 (CIAS)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0657
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年1月14日
◆ページ数:87
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H1 2020, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline landscape.

Cognitive functioning is moderately to severely impair in patients with schizophrenia. Symptoms include poor executive functioning, inability to sustain attention and problems with working memory. Predisposing factors include family history, age and autoimmune diseases. Treatment includes antipsychotic medications.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 8, 5, 13 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cognitive Impairment Associated With Schizophrenia (CIAS) – Overview
Cognitive Impairment Associated With Schizophrenia (CIAS) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cognitive Impairment Associated With Schizophrenia (CIAS) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cognitive Impairment Associated With Schizophrenia (CIAS) – Companies Involved in Therapeutics Development
Anvyl LLC
Astellas Pharma Inc
AstraZeneca Plc
Autifony Therapeutics Ltd
Biogen Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cadent Therapeutics Inc
Coronis NeuroSciences Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
H. Lundbeck AS
INVENT Pharmaceuticals Inc
Iproteos SL
Pfizer Inc
SK Biopharmaceuticals Co Ltd
Spherium Biomed SL
Suven Life Sciences Ltd
Takeda Pharmaceutical Co Ltd
Vanda Pharmaceuticals Inc
Cognitive Impairment Associated With Schizophrenia (CIAS) – Drug Profiles
ASP-4345 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cognitive Impairment Associated With Schizophrenia (CIAS) – Dormant Projects
Cognitive Impairment Associated With Schizophrenia (CIAS) – Discontinued Products
Cognitive Impairment Associated With Schizophrenia (CIAS) – Product Development Milestones
Featured News & Press Releases
Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a “RETOS-Colaboración” grant
Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
Apr 17, 2013: SK Biopharma Announces FDA’s Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Anvyl LLC, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Autifony Therapeutics Ltd, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Biogen Inc, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Co, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Cadent Therapeutics Inc, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Co, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck AS, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by INVENT Pharmaceuticals Inc, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos SL, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Suven Life Sciences Ltd, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H1 2020

【掲載企業】

Anvyl LLC
Astellas Pharma Inc
AstraZeneca Plc
Autifony Therapeutics Ltd
Biogen Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cadent Therapeutics Inc
Coronis NeuroSciences Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
H. Lundbeck AS
INVENT Pharmaceuticals Inc
Iproteos SL
Pfizer Inc
SK Biopharmaceuticals Co Ltd
Spherium Biomed SL
Suven Life Sciences Ltd
Takeda Pharmaceutical Co Ltd
Vanda Pharmaceuticals Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[統合失調症に伴う認知障害 (CIAS)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆